Emyria (ASX: EMD)

Eli Lilly Enters Psychedelics: The Year of the Mushroom

Jul 17, 2026

•

5 min read

Eli Lilly Enters Psychedelics: The Year of the Mushroom

Jason Segal

Emyria (ASX: EMD)

Compass Points North: Six-Month Psychedelic Data

Jul 8, 2026

•

3 min read

Compass Points North: Six-Month Psychedelic Data

Jason Segal

Emyria (ASX: EMD)

Acid Test: Definium’s Positive Phase 3 LSD Readout

Jun 29, 2026

•

4 min read

Acid Test: Definium’s Positive Phase 3 LSD Readout

Jason Segal

Emyria (ASX: EMD)

Jun 17, 2026

•

4 min read

Fireside Conversation with Emyria

Jason Segal

Emyria (ASX: EMD)

Slip Lane to Shroomtown: TGA's Gridlock Unlock

May 28, 2026

•

4 min read

Slip Lane to Shroomtown: TGA's Gridlock Unlock

Jason Segal

Emyria (ASX: EMD)

Spray and Pray: How J&J grew a US$2.3b drug from a three-year bad trip

May 7, 2026

•

6 min read

Spray and Pray: How J&J grew a US$2.3b drug from a three-year bad trip

Jason Segal

Emyria (ASX: EMD)

Apr 21, 2026

•

7 min read

The Economics of Psychedelic Therapy

Jason Segal

Emyria (ASX: EMD)

Apr 20, 2026

•

11 min read

My Second Armchair Pick: Emyria (ASX: EMD)

Jason Segal

Emyria (ASX: EMD)

Eli Lilly Enters Psychedelics: The Year of the Mushroom

Compass Points North: Six-Month Psychedelic Data

Acid Test: Definium’s Positive Phase 3 LSD Readout

Fireside Conversation with Emyria

Slip Lane to Shroomtown: TGA's Gridlock Unlock

Spray and Pray: How J&J grew a US$2.3b drug from a three-year bad trip

The Economics of Psychedelic Therapy

My Second Armchair Pick: Emyria (ASX: EMD)

The Armchair Analyst